Quantcast

Latest Inovio Pharmaceuticals Inc. Stories

2014-08-11 08:29:29

HPV Immune Therapy VGX-3100 to Advance into Phase III PLYMOUTH MEETING, Penn., Aug. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. Total operating expenses were $14.0 million and $26.3 million for the three and six months...

2014-08-01 08:26:14

PLYMOUTH MEETING, Pa., Aug. 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call to report its second quarter 2014 financial results on Monday, August 11, 2014 at 9:00 AM ET. CEO Dr. J. Joseph Kim and CFO Peter Kies will discuss second quarter earnings, provide a corporate update, and participate in a live Q&A with analysts. The update will include clinical development plans for VGX-3100, Inovio's immune therapy...

2014-07-23 08:32:38

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment...

2014-07-01 04:21:59

Inovio Shares Enter No. 1 U.S. Equity Index for Asset Benchmarking PLYMOUTH MEETING, Pa., July 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that it has been added to the Russell Global, Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Approximately $5.2 trillion in assets are currently benchmarked to Russell Indexes. Many investors use mutual funds...

2014-06-23 04:20:45

Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy...

2014-06-17 04:21:35

Expanded License Includes New Product Candidates for Cancer, Infectious Diseases and Novel Immune Activators BLUE BELL, Pa., June 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research...

2014-06-16 04:21:37

BLUE BELL, Pa., June 16, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President & CEO, Dr. J. Joseph Kim, will participate in a panel at the Piper Jaffray GenomeRx Symposium on June 23 to discuss Inovio's leadership in the advancement of novel DNA-based immune therapies. Inovio management will also present a corporate overview at the 2014 BIO International Convention hosted by the Biotechnology Industry Organization (BIO). This year's...

2014-06-11 08:30:52

Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading...

2014-06-10 04:22:14

Inovio Targets Most Rapidly Increasing Cancer in Men BLUE BELL, Pa., June 10, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune...

2014-05-30 04:22:21

BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO." As filed on May 22, 2014, the Company's stockholders approved the proposal of a reverse...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related